Business
Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD)
Arch acquires a new CKD platform that has the potential to produce next-generation CKD drugs for ...
About this update from Arch Biopartners, Inc.
[{"type":"text","content":"Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD)\n\n\n\n\n Arch acquires a new CKD platform that has the potential to produce next-generation CKD drugs for the pharmaceutical industry\n \n\n\n\n Based on a novel mechanism of action involving IL-32 and directly implicated in CKD, discovered in pre-clinical studies led by Dr. Justin Chun\n \n\n\n\n The Company has filed both composition and method of use patents relating to the CKD platform.\n \n\n\n\n The Arch CKD program will be led by Dr. Justin Chun, who joins the Company as a Principal Scientist\n \n\n\n\n CKD is largely an unmet medical need, currently affecting more than 800 million people worldwide and approximately 35 to 38 million in the U.S.\n \n\n\n\n TORONTO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), today announced it has acquired a pre-clinical platform developing new drugs to treat chronic kidney disease (CKD). The platform includes recently filed patents protecting new compositions and methods targeting a novel mechanism of action involving interleukin-32 (IL-32), which is directly implicated in the progression of CKD.\n \n\n Farris Smith, Strategic Advisor to Arch and former CFO of Novo Nordisk Canada, said,\n \n “This new chronic kidney disease program expands the commercial potential of Arch’s kidney drug development pipeline. The assets underlying the CKD program could provide novel, on-target treatment options for a significant unmet need in a major pharmaceutical market. Combined with Arch’s existing acute kidney injury programs, Arch is better positioned for potential new partnership opportunities that can accelerate development and drive long-term value for the Company.”\n \n\n\n Richard Muruve, CEO of Arch Biopartners, said, “\n \n Our entry into the CKD drug development business is a natural evolution for our team that has a strong core competency in nephrology. Today’s news makes Arch Biopartners’ kidney drug portfolio more vital to patients and more valuable to the pharmaceutical industry.”\n \n\n\n Arch obtained the new CKD assets through the acquis...